Search Results
Sep 17, 2025, 12:00 ET CNCF Welcomes 20 New Silver Members Reflecting Broader Cloud Native and AI Adoption
efficiently. Ybor.AI's system automates infrastructure provisioning, application scaffolding (including best practices for security and scalability), sets up CI/CD pipelines, and provides dashboard visibility.About the Newest End User Members CNCF also welcomes several new Silver End User
More news about: CNCF
Sep 17, 2025, 09:00 ET Lilly's oral GLP-1, orforglipron, superior to oral semaglutide in head-to-head trial
https://doi.org/10.2337/cd20-as01Not controlled for family-wise type 1 error.The treatment-regimen estimand represents the estimated average treatment
More news about: Eli Lilly and Company
Sep 17, 2025, 08:00 ET Oasis Security Launches First-Ever Non-Human Identity Management Certification
agentic AI soars, industry-first certification closes the skills gap with best practices for non-human identities at scale and across cloud, SaaS, CI/CD, and AI ecosystems NEW YORK, Sept.
More news about: Oasis Security
Sep 16, 2025, 18:01 ET Lilly's oral GLP-1, orforglipron, demonstrated meaningful weight loss and cardiometabolic improvements in complete ATTAIN-1 results published in The New England Journal of Medicine
https://doi.org/10.2337/cd20-as01 Not controlled for family-wise type 1 error rate.The treatment-regimen estimand represents the estimated average treatment
More news about: Eli Lilly and Company
Sep 16, 2025, 15:29 ET Doppler Achieves ISO/IEC 27001 Certification, Strengthening Trust in The Age of AI-driven Threats
practices without slowing teams down. Security professionals gain audit logs, anomaly detection, and compliance tools. Developers get integrations with CI/CD pipelines, infrastructure tools, and versioned secrets management. For more information, visit our
More news about: Doppler
Sep 16, 2025, 12:29 ET Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals
Chief Scientific and Medical Officer of ImmunityBio. "ANKTIVA is the first FDA-approved immunotherapy to stimulate natural killer cells, CD4+ CD8+ T cells and memory T cells, the very cells that are depleted resulting in lymphopenia, and that play a key role in the immune system's fight against
More news about: USA News Group
Sep 16, 2025, 11:43 ET Antlara Dental unveils timeless white
[email protected] Clinic Contact – Antlara Dental:Fener Mah. Tekelioğlu Cd. No:51 / 1-2Muratpaşa / Antalya, TurkeyPhone: +90 530 202 6868Clinic: +90 242 324 5779Email:
More news about: Antlara Dental
Sep 16, 2025, 10:54 ET DataOps.live Launches Major Upgrade to Deliver AI-Ready Data at Enterprise Scale
DataOps Automation Platform unites CI/CD, observability, governance, and data product delivery to operationalize trusted AI LONDON, Sept.
More news about: DataOps.live
Sep 16, 2025, 08:11 ET Myrtelle Announces Nature Medicine Publication of Interim Results from Its Phase 1/2 Clinical Trial of Investigational Gene Therapy rAAV-Olig001-ASPA for Canavan Disease
initial manifestations of CD. As the disease progresses, seizures, spasticity, difficulties in swallowing, and overall muscle deterioration emerge with most affected children developing life-threatening complications by approximately 10 years of age. Currently, there are no cures for CD, and only palliative
More news about: Myrtelle, Inc
Sep 16, 2025, 05:45 ET BIOVAXYS ANNOUNCES CLOSING OF UNSECURED CONVERTIBLE DEBENTURE OFFERING
from survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers, and also delivers an innate immune activator and a universal CD4 T cell helper peptide. MVP-S has been well tolerated and has demonstrated defined clinical benefit in multiple cancer indications as well as the activation
More news about: BioVaxys Technology Corp.
Sep 15, 2025, 22:27 ET Akeso's Ligufalimab (CD47 mAb) Receives FDA Orphan Drug Designation for Acute Myeloid Leukemia (AML)
2025 /PRNewswire/ -- Akeso Inc. (9926.HK) today announced that its proprietary next-generation humanized IgG4 monoclonal antibody targeting CD47, ligufalimab (AK117), has been granted Orphan Drug Designation (ODD) by the U.S. FDA for the treatment of acute myeloid leukemia (AML). The Orphan
More news about: Akeso, Inc.
Sep 15, 2025, 17:31 ET Bispecific Antibodies in Oncology Market Forecast to Surge Over the Next Decade | DelveInsight
targets of bispecific antibodies in NSCLC, whereas targets such as DLL4 × VEGF-A, PD-L1 × VEGF-A, PD-1/IL-2α, Claudin 18.2 (CLDN18.2)/4-1BB, BCMA × CD3, and others are in other cancers. Promising Companies Developing Technologies for Bispecific Leading companies such as Roche
More news about: DelveInsight Business Research, LLP
Sep 15, 2025, 06:00 ET Gyala Therapeutics unveils first-in-class CAR-T therapy targeting CD84 showing strong preclinical efficacy in hard-to-treat leukemias
Leukemia. The study is the first to show preclinical data of CAR-T cells targeting the CD84 protein, validating GYA01 as a promising therapy for AML and T-ALL and positioning CD84 as a novel target with broad potential across hematological cancers.
More news about: Gyala Therapeutics
Sep 15, 2025, 06:00 ET Gyala Therapeutics unveils first-in-class CAR-T therapy targeting CD84 showing strong preclinical efficacy in hard-to-treat leukemias
Leukemia. The study is the first to show preclinical data of CAR-T cells targeting the CD84 protein, validating GYA01 as a promising therapy for AML and T-ALL and positioning CD84 as a novel target with broad potential across hematological cancers.
More news about: Gyala Therapeutics
Sep 15, 2025, 06:00 ET Gyala Therapeutics stellt erste CAR-T-Therapie ihrer Klasse vor, die auf CD84 abzielt und eine starke präklinische Wirksamkeit bei schwer zu behandelnden Leukämien zeigt.
belegen. Die Studie ist die erste, die präklinische Daten zu CAR-T-Zellen präsentiert, die auf das CD84-Protein abzielen. Damit wird GYA01 als vielversprechende Therapie für AML und T-ALL validiert und CD84 als neues Zielmolekül mit großem Potenzial für verschiedene hämatologische Krebsarten positioniert.
More news about: Gyala Therapeutics
Sep 15, 2025, 06:00 ET Gyala Therapeutics dévoile la première thérapie CAR-T de sa catégorie ciblant CD84, qui montre une forte efficacité préclinique dans les leucémies difficiles à traiter
Cette étude est la première à présenter des données précliniques de cellules CAR-T ciblant la protéine CD84, validant le GYA01 en tant que thérapie prometteuse pour la LMA et la LLA-T et positionnant CD84 comme une nouvelle cible ayant un large potentiel dans les cancers hématologiques.
More news about: Gyala Therapeutics
Sep 15, 2025, 06:00 ET Gyala Therapeutics presenta la primera terapia CAR-T de su clase
Leucemia. El estudio es el primero en mostrar datos preclínicos de células CAR-T dirigidas a la proteína CD84, lo que valida a GYA01 como una terapia prometedora para AML y T-ALL y posiciona a CD84 como una nueva diana con amplio potencial en cánceres hematológicos.
More news about: Gyala Therapeutics